{"entity":{"id":"dbc-664","kind":"drug","name":"DBC-664","aka":[],"tldr":"DBC-664 is an experimental bispecific T-cell engager antibody from Duboce Biopharmaceuticals, in phase 1 trials for ovarian adenocarcinoma, endometrial adenocarcinoma and malignant germ cell tumours and other cancers.","summary":"DBC-664 is a bispecific T-cell engager antibody from Duboce Biopharmaceuticals, with TCG Labs Soleil as partner. A T-cell engager that binds ALPP or ALPPL2 on cancer cells and CD3 on T cells, aimed at antigens that are highly expressed, most evenly in ovarian and endometrial cancers. Its furthest stage is phase 1, for ovarian adenocarcinoma, endometrial adenocarcinoma, malignant germ cell tumours and lung adenocarcinoma. ClinicalTrials.gov registers it in one study linked below. Phase 1a/1b NCT07705035 recruiting; started 17 July 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Duboce Biopharmaceuticals: tcglsoleil.com","url":"https://www.tcglsoleil.com/news/tcg-labs-soleil-highlights-portfolio-momentum-with-three-programs-entering-first-in-human-clinical-trials-across-oncology-and-cardiovascular-disease/"},{"label":"Duboce Biopharmaceuticals: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07705035"},{"label":"ClinicalTrials.gov: trials of DBC-664","url":"https://clinicaltrials.gov/search?intr=DBC-664"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","endometrial","lung-adenocarcinoma","gastric","urothelial"],"sections":[],"technologies":[],"targets":["cd3"],"drugs":[],"companies":["duboce-biopharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07705035"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"DBC-664","modality":"Bispecific T-cell engager antibody","mechanism":"A T-cell engager that binds ALPP or ALPPL2 on cancer cells and CD3 on T cells, aimed at antigens that are highly expressed, most evenly in ovarian and endometrial cancers.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/dbc-664/","neighbours":{"cancer":[{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/"},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"company":[{"id":"duboce-biopharmaceuticals","kind":"company","name":"Duboce Biopharmaceuticals","route":"/companies/duboce-biopharmaceuticals/"}],"trial":[{"id":"nct07705035","kind":"trial","name":"DBC-664 in Adult Patients With Solid Tumors","route":"/trials/nct07705035/"}]}}